Aeglea BioTherapeutics Reports Third Quarter 2022 Financial

/PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as...

Related Keywords

Texas , United States , Jim Kastenmayer , Aeglea Biotherapeutics , Piper Sandler , Exchange Commission , Jp Morgan , European Medicines Agency , Drug Administration , Prnewswire Aeglea Biotherapeutics Inc , Aeglea Biotherapeutics Inc , Nasdaq , Interim Clinical Data , Pegtarviliase Expected , Fourth Quarter , Currently Dosing Cohort , Classical Homocystinuria , Marketing Authorization Application , Key Opinion Leader , Authorization Application , Middle East , Biologics License Application , Inborn Errors , Annual Healthcare Conference , Annual Evercore , Sci Advisors Corporate Access Event , Annual Healthcare Meeting , Drug Designation , Pediatric Disease , Rare Pediatric Disease , Breakthrough Therapy , Fast Track , Orphan Drug , Orphan Drug Designation , European Medicines , Forward Looking , Securities Litigation Reform Act , Quarterly Report , Consolidated Statements , Nc ,